

Randomized comparison between chemotherapy plus best supportive care in advanced gastric cancer

Annals of Oncology

8, 163-168

DOI: [10.1023/a:1008243606668](https://doi.org/10.1023/a:1008243606668)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2013, 7, 351.	0.6	7
2	Chemotherapy of oesophago-gastric cancer. Pathology and Oncology Research, 1998, 4, 87-95.	0.9	7
3	Medical management of advanced gastric cancer. Cancer Treatment Reviews, 1998, 24, 113-118.	3.4	43
4	Treatment of advanced gastric cancer with oral etoposide, leucovorin and tegafur: experience with an oral modification of the etoposide, leucovorin and 5-fluorouracil (ELF) regimen. European Journal of Cancer, 1998, 34, 1128-1130.	1.3	3
5	Evaluation of Clinical Benefit of Chemotherapy in Patients with Upper Gastrointestinal Cancer. Acta Oncologica, 1998, 37, 651-659.	0.8	25
6	Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer. British Journal of Cancer, 1998, 77, 1984-1988.	2.9	17
7	Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer.. Journal of Clinical Oncology, 1998, 16, 434-440.	0.8	82
8	High Doses of 5-Fluorouracil and Epirubicin with or without Cisplatin in Advanced Gastric Cancer: A Randomized Study. Tumori, 1999, 85, 234-238.	0.6	26
9	Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. British Journal of Cancer, 1999, 80, 269-272.	2.9	250
10	Assessment of the quality of life of patients with advanced and end-stage cancer or serious infections with a symptom-based or an impact-based instrument. Supportive Care in Cancer, 1999, 7, 64-70.	1.0	10
11	CPT-11 in gastrointestinal cancer. European Journal of Cancer, 1999, 35, 371-379.	1.3	96
12	Tumor Markers CEA, CA19-9 and CA125 in Monitoring of Response to Systemic Chemotherapy in Patients with Advanced Gastric Cancer. Japanese Journal of Clinical Oncology, 1999, 29, 550-555.	0.6	66
13	Treatment of Advanced Gastric Cancer with Oral Idarubicin, Leucovorin, and Tegafur. Oncology Research and Treatment, 1999, 22, 292-294.	0.8	0
14	Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Journal of Clinical Oncology, 2000, 18, 2648-2657.	0.8	522
15	Combination of Bolus 5-Fluorouracil, Folinic Acid and Mitomycin C in Advanced Gastric Cancer: Results of a Phase II Trial. Oncology Research and Treatment, 2000, 23, 444-447.	0.8	9
16	Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil plus Folinic Acid in Combination with Mitomycin C for the Treatment of Advanced Gastric Cancer. Oncology, 2000, 59, 14-17.	0.9	16
17	Attitudes and Beliefs towards Disease and Treatment in Patients with Advanced Cancer Using Anthroposophical Medicine. Oncology Research and Treatment, 2000, 23, 558-563.	0.8	14
18	Results with Irinotecan in Gastric Carcinoma. Oncology Research and Treatment, 2000, 23, 23-25.	0.8	0

#	ARTICLE	IF	CITATIONS
19	The Treatment of Advanced Gastric Cancer: In Search of the Right Combination. <i>Journal of Clinical Oncology</i> , 2000, 18, 2645-2647.	0.8	16
20	The standard of reporting of health-related quality of life in clinical cancer trials. <i>Journal of Clinical Epidemiology</i> , 2000, 53, 451-458.	2.4	77
21	Sequence-dependent toxicity profile in modified famtx (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study. <i>Pharmacological Research</i> , 2000, 42, 151-156.	3.1	3
22	A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. <i>British Journal of Cancer</i> , 2000, 83, 458-462.	2.9	109
23	Assessment of Quality of Life During Chemotherapy. <i>Acta OncolÃ³gica</i> , 2001, 40, 175-184.	0.8	53
24	AdÃ©nocarcinomes du bas Å“ sophage et du cardia: quelle chimiothÃ©rapie ou chimioradiothÃ©rapie dans le traitement des rÃ©cidives et des mÃ©tastases?. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2001, 5, 107s-112s.	0.6	1
25	A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. <i>European Journal of Cancer</i> , 2001, 37, 1828-1832.	1.3	16
26	Palliative care research. <i>European Journal of Cancer</i> , 2001, 37, 153-159.	1.3	40
28	Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. <i>Annals of Oncology</i> , 2001, 12, 47-51.	0.6	149
29	Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients. <i>British Journal of Cancer</i> , 2001, 85, 1265-1272.	2.9	59
30	Management of upper gastrointestinal cancers. <i>Quality in Health Care: QHC</i> , 2001, 10, 57-64.	1.2	1
31	Neoadjuvant and Adjuvant Chemotherapy of Locally Advanced Stomach Cancer. <i>Oncology Research and Treatment</i> , 2001, 24, 116-121.	0.8	6
32	A Systematic Overview of Chemotherapy Effects in Gastric Cancer. <i>Acta OncolÃ³gica</i> , 2001, 40, 309-326.	0.8	111
33	Assessment of Quality of Life During Chemotherapy. <i>Acta OncolÃ³gica</i> , 2001, 40, 175-184.	0.8	65
34	Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. <i>British Journal of Cancer</i> , 2002, 86, 1864-1870.	2.9	246
35	Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: A low cost effective regimen. <i>British Journal of Cancer</i> , 2002, 86, 213-217.	2.9	13
36	Ralitrexed (Tomudex®) or Nordic-FLv Regimen in Metastatic Colorectal Cancer: A Randomized Phase II Study Focusing on Quality of Life, Patients' Preferences and Health Economics. <i>Journal of Chemotherapy</i> , 2002, 14, 301-308.	0.7	11
37	Etoposide, Doxorubicin and Cisplatin Alternating with 5-Fluorouracil, Doxorubicin and High-Dose Methotrexate in Patients with Advanced Adenocarcinoma of the Stomach or the Gastroesophageal Junction. <i>Journal of Chemotherapy</i> , 2002, 14, 623-626.	0.7	4

#	ARTICLE	IF	CITATIONS
38	Guidelines for the management of oesophageal and gastric cancer. <i>Gut</i> , 2002, 50, v1-v23.	6.1	215
39	Docetaxel in advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 2002, 13, 451-460.	0.7	23
40	Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 2002, 13, 497-503.	0.7	46
41	High-Dose 5-Fluorouracil / Folinic Acid in Combination with Three-Weekly Mitomycin C in the Treatment of Advanced Gastric Cancer. A Phase II Study. <i>Oncology Research and Treatment</i> , 2002, 25, 255-260.	0.8	18
42	Quality-of-life assessment in palliative care. <i>Lancet Oncology</i> , The, 2002, 3, 175-182.	5.1	69
43	Randomized Clinical Trials in Gastric Cancer. <i>Surgical Oncology Clinics of North America</i> , 2002, 11, 111-131.	0.6	5
44	De Gramont Schedule is a Very Low Toxic and Effective Regimen in Low Performance Status Patients Affected by Metastatic Gastric Cancer: Preliminary Report. <i>Tumori</i> , 2002, 88, A21-A24.	0.6	69
45	Chemotherapy options for gastric cancer. <i>Seminars in Radiation Oncology</i> , 2002, 12, 176-186.	1.0	14
46	Pemetrexed in patients with gastrointestinal carcinoma. <i>Seminars in Oncology</i> , 2002, 29, 42-49.	0.8	5
47	Recent developments in the treatment of gastric carcinoma. <i>Current Oncology Reports</i> , 2002, 4, 193-201.	1.8	7
48	Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 525-529.	3.3	154
49	The role of chemotherapy in the current treatment of gastric cancer. <i>Gastric Cancer</i> , 2002, 5, 17-22.	2.7	35
50	Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995-2001. <i>International Journal of Clinical Oncology</i> , 2002, 7, 219-224.	1.0	6
51	Multimodality Treatment of Gastric Cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2002, 34, 29-31.	0.3	1
52	Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. <i>British Journal of Cancer</i> , 2002, 86, 1858-1863.	2.9	42
53	Treatment of Advanced Gastric Cancer with Etoposide, Folinic Acid, and Fluorouracil in the Clinical Setting. <i>Medical Oncology</i> , 2002, 19, 43-54.	1.2	8
54	Paclitaxel, Carboplatin, and Oral Etoposide in Advanced Gastric Adenocarcinoma: Association with Severe Myelotoxicity. <i>Medical Oncology</i> , 2003, 20, 291-294.	1.2	3
55	Status of treatment for advanced gastric carcinoma. <i>Current Oncology Reports</i> , 2003, 5, 210-218.	1.8	15

#	ARTICLE	IF	CITATIONS
56	Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. <i>British Journal of Cancer</i> , 2003, 89, 2051-2056.	2.9	15
57	18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. <i>Gastroenterology</i> , 2003, 125, 1235-1245.	0.6	30
58	Follow-Up Surveillance for Recurrence After Curative Gastric Cancer Surgery Lacks Survival Benefit. <i>Annals of Surgical Oncology</i> , 2003, 10, 898-902.	0.7	89
59	Irinotecan in the treatment of gastric cancer. <i>Annals of Oncology</i> , 2003, 14, ii37-ii40.	0.6	27
60	Gastric cancer: epidemiology, pathology and treatment. <i>Annals of Oncology</i> , 2003, 14, ii31-ii36.	0.6	307
61	Placebo Effects in Oncology. <i>Journal of the National Cancer Institute</i> , 2003, 95, 19-29.	3.0	100
62	Complexities in Prognostication in Advanced Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 98.	3.8	191
63	Current treatments and future perspectives in colorectal and gastric cancer. <i>Annals of Oncology</i> , 2003, 14, ii49-ii55.	0.6	40
64	Irinotecan is active in chemo-naïve patients with metastatic gastric cancer: a phase II multicentric trial. <i>British Journal of Cancer</i> , 2003, 89, 997-1001.	2.9	86
65	Asian Ethnicity-Related Differences in Gastric Cancer Presentation and Outcome Among Patients Treated at a Canadian Cancer Center. <i>Journal of Clinical Oncology</i> , 2003, 21, 2070-2076.	0.8	124
66	Treatment of Advanced Gastric Cancer: Where We Are in 2003. <i>Oncology Research and Treatment</i> , 2003, 26, 214-215.	0.8	0
67	Phase II Study of Paclitaxel and Carboplatin in Patients With Advanced Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 37-41.	0.6	60
68	CPT-11 and Cisplatin in the Treatment of Advanced Gastric Cancer in Asians. <i>Journal of Chemotherapy</i> , 2003, 15, 400-405.	0.7	11
69	Heterogeneity of chemosensitivity of esophageal and gastric carcinoma. <i>Anti-Cancer Drugs</i> , 2003, 14, 397-403.	0.7	20
70	Effective Combination Chemotherapy with Bimonthly Docetaxel and Cisplatin with or without Hematopoietic Growth Factor Support in Patients with Advanced Gastroesophageal Cancer. <i>Oncology</i> , 2003, 65, 211-217.	0.9	22
71	Colon Cancer and Other Gastrointestinal Malignancies. , 2003, , 417-440.		1
72	DOCTOR-PATIENT COMMUNICATION. <i>Annals of Cancer Research and Therapy</i> , 2003, 11, 7-14.	0.1	1
73	Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer. <i>Journal of Korean Medical Science</i> , 2004, 19, 369.	1.1	15

#	ARTICLE	IF	CITATIONS
74	Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. <i>Annals of Oncology</i> , 2004, 15, 1204-1209.	0.6	43
75	Chemotherapy for Advanced Gastric Cancer: Results from Western Clinical Trials. <i>Cancer Reviews: Asia-Pacific</i> , 2004, 02, 51-59.	0.1	0
76	Supportive care for patients with gastrointestinal cancer. <i>The Cochrane Library</i> , 2004, , CD003445.	1.5	31
77	Palliative chemotherapy for advanced gastric cancer. <i>Annals of Oncology</i> , 2004, 15, 1585-1595.	0.6	152
78	The Treatment of Advanced Gastric Cancer: New Findings on the Activity of the Taxanes. <i>Oncologist</i> , 2004, 9, 9-15.	1.9	57
79	Are Chemotherapy Response Rates Related to Treatment-Induced Survival Prolongations in Patients With Advanced Cancer?. <i>Journal of Clinical Oncology</i> , 2004, 22, 1966-1974.	0.8	68
80	(Neo)adjuvant Strategies of Advanced Gastric Carcinoma: Time for a Change?. <i>Digestive Diseases</i> , 2004, 22, 345-350.	0.8	18
81	Innovative Drugs and Strategies in the Treatment of Upper Gastrointestinal Tract Carcinomas. <i>Oncology Research and Treatment</i> , 2004, 27, 47-53.	0.8	0
82	Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 658-663.	0.8	172
83	Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. <i>Annals of Oncology</i> , 2004, 15, 1773-1781.	0.6	145
84	Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2004, 22, 2395-2403.	0.8	455
85	Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. <i>Annals of Oncology</i> , 2004, 15, 64-69.	0.6	125
86	Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma. <i>Annals of Oncology</i> , 2004, 15, 765-769.	0.6	37
87	Chemotherapy in metastatic gastric cancer: population-based perceptions and practice patterns of medical oncologists. <i>British Journal of Cancer</i> , 2004, 90, 1885-1887.	2.9	5
88	Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. <i>British Journal of Cancer</i> , 2004, 91, 18-22.	2.9	83
89	Treatment of metastatic esophagus and gastric cancer. <i>Seminars in Oncology</i> , 2004, 31, 574-587.	0.8	43
92	A cost-benefit analysis of chemotherapy for gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2109-2114.	0.9	2
93	Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Cohort of the Francophone de Cancérologie Digestive Group Study—FFCD 9803. <i>Journal of Clinical Oncology</i> , 2004, 22, 4319-4328.	0.8	256

#	ARTICLE	IF	CITATIONS
94	State of the art treatment for gastric cancer: future directions. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 40-47.	2.2	2
95	Irinotecan for the treatment of gastric cancer. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 48-51.	2.2	4
96	Docetaxel in gastric cancer. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 52-58.	2.2	2
97	What have we learned and where are we going in the treatment of colorectal and gastric cancer?. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 59-62.	2.2	0
98	Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. <i>European Journal of Cancer</i> , 2004, 40, 2260-2268.	1.3	176
99	AdÃ©nocarcinome gastriqueÃ: notions fondamentales, diagnostic et traitement. <i>EMC - Chirurgie</i> , 2004, 1, 47-66.	0.0	3
100	Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination. <i>Anti-Cancer Drugs</i> , 2004, 15, 725-728.	0.7	2
101	Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 477-480.	0.6	41
102	5-Fluorouracil Administered as a 48-Hour Semiintermittent Infusion in Combination With Leucovorin, Cisplatin and Epirubicin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 101-105.	0.6	2
103	What Is the Role of Mitomycin C in Advanced Gastric Cancer?. <i>Oncology Research and Treatment</i> , 2005, 28, 125-126.	0.8	0
104	Phase II Study of Low-Dose Docetaxel/Fluorouracil/Cisplatin in Metastatic Gastric Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 433-438.	0.6	40
105	Chemotherapy and radiotherapy in the management of gastric cancer. <i>Current Opinion in Gastroenterology</i> , 2005, 21, 673-678.	1.0	17
106	Irinotecan (CPT-11) and Mitomycin-C (MMC) as Second-Line Therapy in Advanced Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 581-585.	0.6	39
107	Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. <i>Anti-Cancer Drugs</i> , 2005, 16, 621-625.	0.7	25
108	Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial. <i>Anti-Cancer Drugs</i> , 2005, 16, 435-440.	0.7	20
109	Treatment of stage IV colorectal carcinoma in elderly patients. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 54, 145-155.	2.0	9
110	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 54, 209-241.	2.0	73
111	Irinotecan plus Cisplatin Combination Against Metastatic Gastric Cancer: Phase II Study. <i>Medical Oncology</i> , 2005, 22, 153-160.	1.2	7

#	ARTICLE	IF	CITATIONS
112	Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. <i>British Journal of Cancer</i> , 2005, 92, 246-251.	2.9	34
113	Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. <i>British Journal of Cancer</i> , 2005, 92, 1976-1983.	2.9	138
114	A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. <i>British Journal of Cancer</i> , 2005, 92, 1644-1649.	2.9	171
115	Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. <i>British Journal of Cancer</i> , 2005, 92, 2122-2128.	2.9	91
116	Longitudinal quality of life study in patients with metastatic gastric cancer. <i>Gastroenterologie Clinique Et Biologique</i> , 2005, 29, 1113-1124.	0.9	15
117	Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer. <i>BMC Cancer</i> , 2005, 5, 87.	1.1	2
118	Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 563-568.	1.1	29
119	Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study. <i>International Journal of Clinical Oncology</i> , 2005, 10, 251-255.	1.0	6
121	Gastric cancer. treatment of advanced disease and new drugs. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 3122.	3.0	7
122	Quality of life in gastric cancer. <i>World Journal of Gastroenterology</i> , 2005, 11, 3189.	1.4	57
123	Docetaxel + 5-Fluorouracil + Cisplatin 3-day Combination Chemotherapy as a First-line Treatment in Patients with Unresectable Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 380-385.	0.6	15
124	A Phase II Study of Epirubicin, Cisplatin and Uracil-Tegafur for Advanced Gastric Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 13-17.	0.6	12
125	Evolving Chemotherapy for Advanced Gastric Cancer. <i>Oncologist</i> , 2005, 10, 49-58.	1.9	177
126	A Phase II Study of Docetaxel and Cisplatin in Patients with Gastric Cancer Recurring After or Progressing During 5-FU/Platinum Treatment. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 727-732.	0.6	13
127	Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. <i>British Journal of Cancer</i> , 2005, 92, 1850-1854.	2.9	54
128	Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. <i>British Journal of Cancer</i> , 2005, 93, 190-194.	2.9	82
129	Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5660-5667.	0.8	211
130	Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Gastric Cancer (OCSC) Tj ETQq1_1_0.784314 rgBT 0,6 31	0.6	31

#	ARTICLE	IF	CITATIONS
131	Phase II Trial of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Gastric Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 720-726.	0.6	17
132	Infusional 5-Fluorouracil and Mitomycin C: An Effective Regimen in the Treatment of Advanced Gastric Cancer. Oncology Research and Treatment, 2005, 28, 128-132.	0.8	6
133	Second-Line Chemotherapy of Advanced Disseminated Gastric Cancer after Cisplatin, Infusional 5-Fluorouracil, Folinic Acid (PLF): Benefit Dependant on Progression-Free Interval after First-Line Therapy. Oncology Research and Treatment, 2005, 28, 499-502.	0.8	15
134	A Demographic and Prognostic Approach to Defining the End of Life. Journal of Palliative Medicine, 2005, 8, s-12-s-21.	0.6	32
135	Gastric and gastro-oesophageal cancer therapy. Expert Opinion on Pharmacotherapy, 2005, 6, 2805-2812.	0.9	6
136	Gastrointestinal cancer: recent developments in medical oncology. European Journal of Surgical Oncology, 2005, 31, 453-460.	0.5	25
137	Status of Newer Chemotherapeutic Strategies for the Treatment of Metastatic Gastric Cancer. American Journal of Cancer, 2005, 4, 65-70.	0.4	0
138	Chemotherapy for advanced gastric cancer. , 2005, , CD004064.		55
139	A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients with Advanced Adenocarcinoma of the Stomach or Esophagus. Cancer Investigation, 2006, 24, 229-234.	0.6	11
140	Recent developments in the systemic therapy of advanced gastroesophageal malignancies. Expert Opinion on Investigational Drugs, 2006, 15, 131-153.	1.9	7
141	Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data. Journal of Clinical Oncology, 2006, 24, 2903-2909.	0.8	1,055
142	Newly diagnosed metastatic gastric cancer. Community Oncology, 2006, 3, 769-770.	0.2	0
143	Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III randomized trial. Pancreatology, 2006, 6, 454-463.	0.5	29
144	Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. European Journal of Cancer, 2006, 42, 827-834.	1.3	87
145	Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. Brazilian Journal of Medical and Biological Research, 2006, 39, 431-440.	0.7	32
146	Irinotecan, Fluorouracil and Folinic ACID (FOLFIRI) as Effective Treatment Combination for Patients with Advanced Gastric Cancer in Poor Clinical Condition. Tumori, 2006, 92, 379-383.	0.6	11
147	Palliative treatments for patients with inoperable gastroesophageal cancers. International Journal of Palliative Nursing, 2006, 12, 306-317.	0.2	3
151	Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anti-Cancer Drugs, 2006, 17, 225-229.	0.7	58

#	ARTICLE	IF	CITATIONS
152	Oxaliplatin in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV) in Patients With Metastatic Gastric Cancer (MGC). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 371-375.	0.6	53
153	Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. <i>British Journal of Cancer</i> , 2006, 95, 450-456.	2.9	10
155	Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. <i>Gastric Cancer</i> , 2006, 9, 140-143.	2.7	3
156	Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy. <i>International Journal of Clinical Oncology</i> , 2006, 11, 367-374.	1.0	4
157	Is There a Role for Palliative Gastrectomy in Patients with Stage IV Gastric Cancer?. <i>World Journal of Surgery</i> , 2006, 30, 21-27.	0.8	88
158	Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 91-96.	1.1	35
159	Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 289-294.	1.1	30
160	Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 17-21.	1.1	21
161	A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 313-320.	1.1	8
162	Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. <i>International Journal of Cancer</i> , 2006, 119, 783-791.	2.3	80
163	Docetaxel in the treatment of gastric cancer. <i>Future Oncology</i> , 2006, 2, 603-620.	1.1	12
164	A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer. <i>Oncology</i> , 2006, 70, 63-70.	0.9	15
165	Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients. <i>Annals of Oncology</i> , 2006, 17, 1665-1672.	0.6	30
166	Quality of Life in Patients with Oesophageal and Gastric Cancer: An Overview. <i>Oncology</i> , 2006, 70, 391-402.	0.9	69
167	Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. <i>Annals of Oncology</i> , 2006, 17, 652-656.	0.6	47
168	Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. <i>Annals of Oncology</i> , 2006, 17, 1529-1532.	0.6	14
169	Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 4991-4997.	0.8	1,772
170	Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. <i>British Journal of Cancer</i> , 2006, 94, 1130-1135.	2.9	62

#	ARTICLE	IF	CITATIONS
171	Multi-Institutional Phase II Study of S-1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetic and Pharmacogenomic Evaluations. <i>Oncologist</i> , 2007, 12, 543-554.	1.9	33
172	Combination Chemotherapy with Capecitabine (X) and Cisplatin (P) as First Line Treatment in Advanced Gastric Cancer: Experience of 223 Patients with Prognostic Factor Analysis. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 30-37.	0.6	36
173	Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 3210-3216.	0.8	164
174	Efficacy and safety of cisplatin and capecitabine in combination as first line treatment for unselected patients with advanced gastric cancer. <i>Acta Oncologica</i> , 2007, 46, 397-399.	0.8	2
175	Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer. <i>Acta Oncologica</i> , 2007, 46, 1032-1034.	0.8	8
176	Advances in the treatment of patients with gastric adenocarcinoma. <i>Acta Oncologica</i> , 2007, 46, 277-285.	0.8	47
177	Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. <i>Journal of Clinical Oncology</i> , 2007, 25, 2580-2585.	0.8	68
178	Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELLUF) as first-line chemotherapy in metastatic gastric cancer. <i>Acta Oncologica</i> , 2007, 46, 324-329.	0.8	3
179	Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer. <i>Acta Oncologica</i> , 2007, 46, 330-335.	0.8	8
180	Phase II Study of a Combination of Irinotecan and S-1 in Patients with Advanced Gastric Cancer (OGSG0002). <i>Oncology</i> , 2007, 73, 65-71.	0.9	26
181	Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer. <i>Oncology</i> , 2007, 73, 2-8.	0.9	6
182	Phase II Study of Biweekly Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Gastric Cancer: Korea Japan Collaborative Study Group Trial. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 501-508.	0.6	7
183	Docetaxel Monotherapy as a Second-line Treatment after Failure of Fluoropyrimidine and Platinum in Advanced Gastric Cancer: Experience of 154 Patients with Prognostic Factor Analysis. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 936-941.	0.6	41
184	Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 3205-3209.	0.8	237
185	A Multicentre Phase II Study of Docetaxel plus Cisplatin for the Treatment of Advanced Gastric Cancer. <i>Chemotherapy</i> , 2007, 53, 454-460.	0.8	10
186	Phase I/II Study of a Combination of S-1 and Weekly Paclitaxel in Patients with Advanced or Recurrent Gastric Cancer. <i>Oncology</i> , 2007, 72, 219-225.	0.9	9
187	Surveillance Program for Recurrence after Curative Gastric Cancer Surgery. <i>Visceral Medicine</i> , 2007, 23, 392-398.	0.5	4
188	Chemotherapy of advanced gastric cancer. <i>Cancer Treatment Reviews</i> , 2007, 33, 315-324.	3.4	124

#	ARTICLE	IF	CITATIONS
189	Chemotherapy for advanced gastric cancer: across the years for a standard of care. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 797-808.	0.9	41
190	Second-line therapy for esophageal cancer. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 871-876.	1.1	1
191	Pharmacotherapy for Oesophagogastric Cancer. <i>Drugs</i> , 2007, 67, 2539-2556.	4.9	4
192	Mitomycin C plus Infusional 5-Fluorouracil in Platinum-Refractory Gastric Adenocarcinoma: An Extended Multicenter Phase II Study. <i>Oncology Research and Treatment</i> , 2007, 30, 235-240.	0.8	11
193	Phase II Study of Docetaxel and Cisplatin as First-line Chemotherapy in Patients with Recurrent or Metastatic Gastric Cancer. <i>Cancer Research and Treatment</i> , 2007, 39, 49.	1.3	6
194	Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer. <i>Journal of Korean Medical Science</i> , 2007, 22, S115.	1.1	24
196	Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups?. <i>Journal of Surgical Oncology</i> , 2007, 95, 118-122.	0.8	52
197	Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 61, 44-51.	2.0	37
198	Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. <i>British Journal of Cancer</i> , 2007, 97, 851-856.	2.9	27
199	The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. <i>European Journal of Cancer Care</i> , 2007, 17, 070611034311012-???	0.7	4
200	Immediate versus delayed chemotherapy in patients with asymptomatic incurable metastatic cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007, 3, 187-198.	0.7	3
201	Palliative management of gastric cancer. <i>Surgical Oncology</i> , 2007, 16, 267-275.	0.8	33
202	A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 315-321.	1.1	18
203	Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2007, 10, 104-111.	2.7	29
204	Management of gastric adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2007, 9, 438-442.	1.2	18
205	Multimodal treatment of gastric cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 965-981.	1.0	35
206	Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy. <i>Quality of Life Research</i> , 2008, 17, 207-214.	1.5	44
207	A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 631-637.	1.1	65

#	ARTICLE	IF	CITATIONS
208	The effect of p53 gene expression on the inhibition of cell proliferation by paclitaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 379-385.	1.1	7
209	A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 1103-1109.	1.1	19
210	The Changing Use of Palliative Chemotherapy for Recurrent Esophagogastric Cancer: A Single Center Retrospective 15-Year Review. <i>Journal of Gastrointestinal Cancer</i> , 2008, 39, 51-57.	0.6	2
211	Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 84-90.	2.0	15
212	A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. <i>British Journal of Cancer</i> , 2008, 98, 316-322.	2.9	34
213	A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. <i>British Journal of Cancer</i> , 2008, 99, 584-590.	2.9	127
214	Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer. <i>British Journal of Cancer</i> , 2008, 99, 858-861.	2.9	20
215	Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?. <i>British Journal of Cancer</i> , 2008, 99, 1402-1407.	2.9	88
216	Palliative Medicine Review: Prognostication. <i>Journal of Palliative Medicine</i> , 2008, 11, 84-103.	0.6	217
217	Epirubicin, taxotere and fluorouracil modulated by folinic acid in the treatment of advanced gastric cancer: A phase II study of the Gruppo Oncologico dell'€™ Italia Meridionale (GOIM). <i>European Journal of Cancer, Supplement</i> , 2008, 6, 107-112.	2.2	1
218	Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. <i>New England Journal of Medicine</i> , 2008, 358, 36-46.	13.9	2,052
219	The herb medicine formula "Yang Wei Kang Liu" improves the survival of late stage gastric cancer patients and induces the apoptosis of human gastric cancer cell line through Fas/Fas ligand and Bax/Bcl-2 pathways. <i>International Immunopharmacology</i> , 2008, 8, 1196-1206.	1.7	23
220	Oral Fluoropyrimidines (Capecitabine or S-1) and Cisplatin as First Line Treatment in Elderly Patients with Advanced Gastric Cancer: A Retrospective Study. <i>Japanese Journal of Clinical Oncology</i> , 2008, 39, 43-48.	0.6	23
221	The role of UFT in advanced gastric cancer. <i>Annals of Oncology</i> , 2008, 19, 1045-1052.	0.6	10
222	Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. <i>Annals of Oncology</i> , 2008, 19, 729-733.	0.6	37
223	Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. <i>Annals of Oncology</i> , 2008, 19, 1882-1887.	0.6	221
224	Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. <i>Journal of Clinical Oncology</i> , 2008, 26, 1435-1442.	0.8	689
225	Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. <i>British Journal of Cancer</i> , 2008, 98, 1305-1311.	2.9	21

#	ARTICLE	IF	CITATIONS
226	Emerging drugs in the treatment of advanced gastric cancer. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 135-144.	1.0	11
227	The treatment of advanced gastric cancer: current strategies and future perspectives. <i>Annals of Oncology</i> , 2008, 19, v103-v107.	0.6	77
228	Clinical benefit of palliative radiation therapy in advanced gastric cancer. <i>Acta Oncologica</i> , 2008, 47, 421-427.	0.8	96
229	Multi-Center Phase II Study for Combination Therapy with Paclitaxel/Doxifluridine to Treat Advanced/Recurrent Gastric Cancer Showing Resistance to S-1 (OGSG 0302). <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 176-181.	0.6	25
230	Irinotecan Combined with 5-Fluorouracil and Leucovorin as Second-line Chemotherapy for Metastatic or Relapsed Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 589-595.	0.6	31
231	Capecitabine in the treatment of advanced gastric cancer. <i>Future Oncology</i> , 2008, 4, 179-198.	1.1	11
232	Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 2008, 19, 1013-1018.	0.7	22
233	Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 2008, 19, 283-288.	0.7	6
234	Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 2008, 19, 825-831.	0.7	19
235	Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. <i>Anti-Cancer Drugs</i> , 2008, 19, 303-307.	0.7	27
237	Phase II Study of Paclitaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer. <i>Journal of Korean Medical Science</i> , 2008, 23, 586.	1.1	12
238	Docetaxel as Salvage Therapy in Highly Pretreated and Drug Resistant Gastrointestinal Carcinomas. <i>Clinical Medicine Oncology</i> , 2008, 2, CMO.S919.	0.2	1
239	A Pilot Study of Irinotecan Combined with 5-Fluorouracil and Leucovorin for the Treatment of Chinese Patients with Locally Advanced and Metastatic Gastric Cancer. <i>Tumori</i> , 2009, 95, 432-437.	0.6	3
240	Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. <i>World Journal of Gastrointestinal Oncology</i> , 2009, 1, 47.	0.8	5
241	Phase II Study of Irinotecan, High-dose 5-fluorouracil, and Leucovorin Combination Chemotherapy in Taxane and Cisplatin-based Chemotherapy-refractory Metastatic Gastric Cancer. <i>Chonnam Medical Journal</i> , 2009, 45, 79.	0.1	0
242	Feasibility Study of Biweekly Capecitabine, Oxaliplatin, and Irinotecan in Patients with Untreated Advanced Gastric Cancer. <i>Tumori</i> , 2009, 95, 43-47.	0.6	9
243	Trastuzumab for gastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1543-1551.	1.4	38
244	Improving the Methodologic and Ethical Validity of Best Supportive Care Studies in Oncology: Lessons From a Systematic Review. <i>Journal of Clinical Oncology</i> , 2009, 27, 5476-5486.	0.8	44

#	ARTICLE	IF	CITATIONS
245	A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status. <i>Oncology</i> , 2009, 77, 349-357.	0.9	6
246	Novel investigational drugs for gastric cancer. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 945-955.	1.9	17
247	ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1745-1751.	1.1	14
248	Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 237-243.	0.6	14
249	A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. <i>BMC Cancer</i> , 2009, 9, 110.	1.1	37
250	Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 29-38.	1.2	40
251	Combination chemotherapy of S-1 and taxanes in Korea. <i>Gastric Cancer</i> , 2009, 12, 31-37.	2.7	0
252	Clinical development of S-1 plus cisplatin therapy as first-line treatment for advanced gastric cancer. <i>Gastric Cancer</i> , 2009, 12, 50-54.	2.7	1
253	Clinical observation of capecitabine plus oxaliplatin in treatment of 68 cases with advanced gastric cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2009, 8, 411-414.	0.1	0
255	Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. <i>Toxicology</i> , 2009, 256, 135-140.	2.0	41
256	Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 213-218.	1.1	6
257	A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 363-370.	1.1	74
258	Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 433-439.	1.1	14
259	A multiple-center phase II study of biweekly oxaliplatin and tegafurâ€“uracil/leucovorin for chemonaive patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 819-825.	1.1	5
260	A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 347-353.	1.1	8
261	Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 549-555.	1.1	16
262	Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 159-166.	1.1	6
263	Phase II study of Sâ€“1 and irinotecan combination chemotherapy as a firstâ€“line therapy for patients with advanced gastric cancer. <i>Korean Cancer Study Group Protocol ST05â€“02. Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 46-54.	0.7	3

#	ARTICLE	IF	CITATIONS
264	Systemic treatment of gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 216-234.	2.0	25
265	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 127-164.	2.0	347
266	Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1351-1364.	1.9	18
267	Gastric cancer. <i>Lancet, The</i> , 2009, 374, 477-490.	6.3	871
268	6563 Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 379.	2.2	0
269	Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 2009, 20, 287-293.	0.7	19
270	Phase II study of capecitabine plus cisplatin in patients with gastric cancer. <i>Anti-Cancer Drugs</i> , 2009, 20, 191-196.	0.7	4
271	A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer. <i>Anti-Cancer Drugs</i> , 2009, 20, 941-945.	0.7	7
272	Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2010, 3, 55-59.	0.6	12
273	A Phase I Trial of Oblimersen Sodium in Combination With Cisplatin and 5-Fluorouracil in Patients With Advanced Esophageal, Gastroesophageal Junction, and Gastric Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 61-65.	0.6	17
274	A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 56-60.	0.6	3
275	Preliminary trial of adjuvant surgery for advanced gastric cancer. <i>Oncology Letters</i> , 2010, 1, 743-747.	0.8	36
276	Clinical Outcomes and Prognostic Factors of Metastatic Gastric Carcinoma Patients Who Experience Gastrointestinal Perforation During Palliative Chemotherapy. <i>Annals of Surgical Oncology</i> , 2010, 17, 3163-3172.	0.7	11
277	Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 473-480.	1.1	23
278	Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 579-587.	1.1	32
279	Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 797-805.	1.1	23
280	Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1059-1064.	1.2	16
281	Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer. <i>Gastric Cancer</i> , 2010, 13, 95-100.	2.7	1

#	ARTICLE	IF	CITATIONS
282	Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. <i>Gastric Cancer</i> , 2010, 13, 155-161.	2.7	25
283	Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis. <i>International Journal of Clinical Oncology</i> , 2010, 15, 287-293.	1.0	3
284	Oxaliplatin and teniposide can inhibit the proliferation and induce the apoptosis of gastric cancer cell line BGC-823 synergistically. <i>Chinese-German Journal of Clinical Oncology</i> , 2010, 9, 149-152.	0.1	0
285	The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. <i>Medical Oncology</i> , 2010, 27, 680-684.	1.2	17
286	Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer. <i>Medical Oncology</i> , 2010, 27, 992-997.	1.2	4
287	Benefit of Post-operative Surveillance for Recurrence after Curative Resection for Gastric Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 969-976.	0.9	32
288	Synergistic effects of Î²-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. <i>Phytomedicine</i> , 2010, 17, 575-580.	2.3	39
289	Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer. <i>BMC Cancer</i> , 2010, 10, 583.	1.1	15
290	Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. <i>Cancer</i> , 2010, 116, 2511-2518.	2.0	54
291	A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 298-305.	0.7	5
292	BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. <i>Cancer Science</i> , 2010, 101, 1247-1254.	1.7	68
293	A Review of Docetaxel: Its Use in the Treatment of Gastric Cancer. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S5191.	0.4	0
295	Efficacy and Feasibility of Combination Chemotherapy with S-1 and Cisplatin (2 Weeks Regimen) for Advanced Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 302-306.	0.6	2
296	Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens. <i>Journal of Oncology Pharmacy Practice</i> , 2010, 16, 173-178.	0.5	4
297	A Phase II Trial of Epirubicin, Oxaliplatin, and Capecitabine (EOX) as First-Line Chemotherapy in Advanced Gastric Cancer: A Chinese Single-Center Experience. <i>Chemotherapy</i> , 2010, 56, 171-177.	0.8	6
298	DNA polymeraseÎ· protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. <i>Journal of Translational Medicine</i> , 2010, 8, 126.	1.8	53
299	Chemotherapy for advanced gastric cancer. , 2010, , CD004064.		422
300	Advanced gastric cancer “ Slow but steady progress. <i>Cancer Treatment Reviews</i> , 2010, 36, 384-392.	3.4	141

#	ARTICLE	IF	CITATIONS
301	A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. <i>European Journal of Cancer</i> , 2010, 46, 885-891.	1.3	46
302	The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial. <i>European Journal of Cancer</i> , 2010, 46, 3200-3204.	1.3	56
303	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. <i>Lancet</i> , The, 2010, 376, 687-697.	6.3	5,899
304	Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. <i>Cancer Treatment Reviews</i> , 2010, 36, S11-S15.	3.4	77
305	Phase I study of Paclitaxel, Cisplatin and 5-fluorouracil combination chemotherapy for unresectable / recurrent gastric cancer. <i>Advances in Medical Sciences</i> , 2010, 55, 137-142.	0.9	6
306	Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. <i>Acta OncolÅ³gica</i> , 2010, 49, 1246-1252.	0.8	10
307	Guidelines for the management of oesophageal and gastric cancer. <i>Gut</i> , 2011, 60, 1449-1472.	6.1	570
308	Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 48-54.	0.7	6
309	Evolving standards of care in advanced gastric cancer. <i>Future Oncology</i> , 2011, 7, 1441-1450.	1.1	3
310	Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. <i>European Journal of Cancer</i> , 2011, 47, 1146-1151.	1.3	29
311	Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <i>European Journal of Cancer</i> , 2011, 47, 2306-2314.	1.3	512
312	What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy?. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1843-1850.	1.1	0
313	Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases. <i>Cancer Research and Treatment</i> , 2011, 43, 244-249.	1.3	31
315	Capecitabine in Combination with Oxaliplatin as First-Line Therapy for Advanced Gastric Cancer: A Case Report. <i>Tumori</i> , 2011, 97, 115-118.	0.6	1
316	Best Supportive Care: A Euphemism for No Care or a Standard of Good Care?. <i>Seminars in Oncology</i> , 2011, 38, 351-357.	0.8	10
317	Inhibition of p600 Expression Suppresses Both Invasiveness and Anoikis Resistance of Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 2057-2065.	0.7	9
318	A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. <i>Investigational New Drugs</i> , 2011, 29, 366-373.	1.2	73
319	A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. <i>Investigational New Drugs</i> , 2011, 29, 1029-1037.	1.2	269

#	ARTICLE	IF	CITATIONS
320	Phase II study of sunitinib as second-line treatment for advanced gastric cancer. <i>Investigational New Drugs</i> , 2011, 29, 1449-1458.	1.2	179
321	Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1499-1504.	1.2	3
322	Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. <i>Gastric Cancer</i> , 2011, 14, 219-225.	2.7	21
323	Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2011, 14, 249-256.	2.7	27
324	Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer. <i>Gastric Cancer</i> , 2011, 14, 332-338.	2.7	5
325	Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 527-532.	1.1	11
326	A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 913-921.	1.1	69
327	<i>Gastric Cancer. Current Problems in Cancer</i> , 2011, 35, 97-127.	1.0	10
328	Thymidine Phosphorylase/ β -tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. <i>BMC Cancer</i> , 2011, 11, 177.	1.1	25
329	A Systems Pharmacology Analysis of Major Chemotherapy Combination Regimens Used in Gastric Cancer Treatment: Predicting Potential New Protein Targets and Drugs. <i>Current Cancer Drug Targets</i> , 2011, 11, 849-869.	0.8	16
330	Comparison of Cisplatin-5-Fluorouracil-Folinic Acid versus Modified Docetaxel-Cisplatin-5-Fluorouracil Regimens in the First-Line Treatment of Metastatic Gastric Cancer. <i>Chemotherapy</i> , 2011, 57, 230-235.	0.8	18
331	Second-Line Docetaxel Plus Cisplatin for Advanced Gastric Cancer Showing Resistance to S-1. <i>Journal of Chemotherapy</i> , 2011, 23, 44-48.	0.7	0
332	Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer. <i>Oncology</i> , 2011, 80, 359-365.	0.9	18
333	A Phase II Multi-Center Study of Triple Therapy with Paclitaxel, S-1 and Cisplatin in Patients with Advanced Gastric Cancer. <i>Oncology</i> , 2011, 80, 76-83.	0.9	20
334	The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. <i>Annals of Oncology</i> , 2012, 23, 1699-1705.	0.6	25
335	Comparison of Two Inflammation-Based Prognostic Scores in Patients with Unresectable Advanced Gastric Cancer. <i>Oncology</i> , 2012, 83, 292-299.	0.9	71
336	Modified FOLFOX-6 Therapy for Heavily Pretreated Advanced Gastric Cancer Refractory to Fluorouracil, Irinotecan, Cisplatin and Taxanes: A Retrospective Study. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 686-690.	0.6	12
337	How Does Inhibition of the Renin-Angiotensin System Affect the Prognosis of Advanced Gastric Cancer Patients Receiving Platinum-Based Chemotherapy?. <i>Oncology</i> , 2012, 83, 354-360.	0.9	41

#	ARTICLE	IF	CITATIONS
338	Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. <i>British Journal of Cancer</i> , 2012, 106, 1469-1474.	2.9	102
339	Nonpalliative Surgical Resection for Gastric Cancer Patients with Distant Metastasis. <i>Journal of Investigative Surgery</i> , 2012, 25, 100-106.	0.6	10
340	A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients. <i>Chemotherapy</i> , 2012, 58, 411-418.	0.8	17
341	The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. <i>Journal of Chemotherapy</i> , 2012, 24, 217-220.	0.7	9
342	18F-FDG PET-CT for detecting recurrent gastric adenocarcinoma. <i>Nuclear Medicine Communications</i> , 2012, 33, 960-966.	0.5	10
343	Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination. <i>Oncology Letters</i> , 2012, 3, 662-666.	0.8	8
344	Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells. <i>Experimental and Therapeutic Medicine</i> , 2012, 4, 291-296.	0.8	27
345	Management of Gastroesophageal Junction Tumors. <i>Surgical Clinics of North America</i> , 2012, 92, 1199-1212.	0.5	16
346	Second-line chemotherapy for advanced gastric cancer in Korea. <i>Gastric Cancer</i> , 2012, 15, 345-354.	2.7	8
347	A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer. <i>Gastric Cancer</i> , 2012, 15, 363-369.	2.7	22
348	Bax Expression Is Predictive of Favorable Clinical Outcome in Chemonaive Advanced Gastric Cancer Patients Treated with Capecitabine, Oxaliplatin, and Irinotecan Regimen. <i>Translational Oncology</i> , 2012, 5, 155-159.	1.7	19
349	Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer. <i>Acta Oncologica</i> , 2012, 51, 112-121.	0.8	15
350	Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer. <i>European Journal of Cancer</i> , 2012, 48, 510-517.	1.3	18
351	Phase I study of imatinib, cisplatin and 5-fluorouracil or capecitabine in advanced esophageal and gastric adenocarcinoma. <i>BMC Cancer</i> , 2012, 12, 587.	1.1	8
352	Current Status and Future Directions in Gastric Cancer with Peritoneal Dissemination. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 625-633.	0.6	49
353	Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2012, 24, 291-298.	0.7	13
354	A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 665-672.	1.1	6
355	Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. <i>British Journal of Cancer</i> , 2012, 106, 1591-1597.	2.9	14

#	ARTICLE	IF	CITATIONS
357	Chemotherapy for gastric cancer patients – time for personalization in medicine?. Wspolczesna Onkologia, 2012, 1, 86-89.	0.7	2
358	Significance of palliative gastrectomy for late-stage gastric cancer patients. Journal of Surgical Oncology, 2012, 106, 862-871.	0.8	39
360	Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients. Gastric Cancer, 2012, 15, 305-312.	2.7	9
361	Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Investigational New Drugs, 2012, 30, 306-315.	1.2	51
362	Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, single-institution experience. Gastric Cancer, 2012, 15, 106-110.	2.7	6
363	Clinical and Prognostic Significance of Coagulation Assays in Gastric Cancer. Journal of Gastrointestinal Cancer, 2013, 44, 285-292.	0.6	54
364	Advanced or metastatic gastric cancer in elderly patients: clinicopathological, prognostic factors and treatments. Clinical and Translational Oncology, 2013, 15, 376-383.	1.2	12
365	Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). Clinical and Translational Oncology, 2013, 15, 403-408.	1.2	9
366	Weekly paclitaxel and S-1 combination chemotherapy for advanced gastric cancer. Chinese-German Journal of Clinical Oncology, 2013, 12, 273-278.	0.1	0
367	Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients. International Journal of Clinical Oncology, 2013, 18, 510-516.	1.0	6
368	Cancer de l'estomac métastatique : traitement médical. Oncologie, 2013, 15, 161-168.	0.2	0
369	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. Journal of the National Cancer Institute, 2013, 105, 1667-1670.	3.0	78
370	Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. European Journal of Cancer, 2013, 49, 1565-1577.	1.3	136
371	Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study. Investigational New Drugs, 2013, 31, 1573-1579.	1.2	68
372	FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. Journal of Experimental and Clinical Cancer Research, 2013, 32, 67.	3.5	22
373	Assessment of Advanced Gastric Cancer Management in the United States. Annals of Surgical Oncology, 2013, 20, 2124-2131.	0.7	11
374	Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer, 2013, 13, 577.	1.1	90
375	Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 2111-2116.	1.2	12

#	ARTICLE	IF	CITATIONS
376	Current questions for the treatment of advanced gastric cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 60-67.	3.4	150
377	Multidisciplinary Management of Gastric Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 247-264.	0.6	11
378	Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 341-356.	1.9	25
379	Surgery after Preoperative Chemotherapy for Patients with Unresectable Advanced Gastric Cancer. <i>Oncology</i> , 2013, 85, 241-247.	0.9	12
380	Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma. <i>BioMed Research International</i> , 2013, 2013, 1-6.	0.9	1
381	Sequential Chemotherapies for Advanced Gastric Cancer: A Retrospective Analysis of 111 Patients. <i>Oncology</i> , 2013, 85, 262-268.	0.9	8
382	Follow-Up: The Evidence. <i>Digestive Surgery</i> , 2013, 30, 159-168.	0.6	33
383	Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. <i>Cancer Medicine</i> , 2013, 2, 325-333.	1.3	20
384	Serum CA19-9 as a prognostic factor in patients with metastatic gastric cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 324-330.	0.7	28
385	Gastric cancer: past accomplishments, present approaches and future aspirations. <i>Clinical Practice (London, England)</i> , 2013, 10, 47-77.	0.1	0
386	What Is a Useful Strategy for Estimating Survival in Palliative Care Settings for Persons With Advanced Cancer?. , 2013, , 235-240.		1
387	Clinical Practice Guidelines for Gastric Cancer in Korea: An Evidence-Based Approach. <i>Journal of Gastric Cancer</i> , 2014, 14, 87.	0.9	163
389	Oxidative Stress-Related Genetic Polymorphisms Are Associated with the Prognosis of Metastatic Gastric Cancer Patients Treated with Epirubicin, Oxaliplatin and 5-Fluorouracil Combination Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e116027.	1.1	22
390	Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 110.	3.5	23
391	Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: Results of a multicenter phase I/II study. <i>Acta Oncologica</i> , 2014, 53, 392-398.	0.8	15
392	Her-2 Positive Gastric Cancer Presented with Thrombocytopenia and Skin Involvement: A Case Report. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-5.	0.2	3
393	A Case of Gingival Candidiasis with Bone Destruction on Gastric Cancer Patient Receiving Cytotoxic Chemotherapy. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-5.	0.2	2
394	Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. <i>Oncology Reports</i> , 2014, 31, 1863-1870.	1.2	89

#	ARTICLE	IF	CITATIONS
395	Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer. <i>Journal of Chemotherapy</i> , 2014, 26, 117-121.	0.7	7
396	Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 887-900.	1.1	29
397	Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients. <i>World Journal of Surgical Oncology</i> , 2014, 12, 406.	0.8	19
398	Effect of the Weekly Administration of Liposome Paclitaxel Combined with S-1 on Advanced Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 208-213.	0.6	7
399	The effects of chemotherapy on C-reactive protein and quality of life in cancer patients. <i>Turk Onkoloji Dergisi</i> , 2014, 29, 1-10.	0.0	2
400	Predictive factors to targeted treatment in gastrointestinal carcinomas. <i>Cancer Biomarkers</i> , 2014, 14, 151-162.	0.8	5
401	S-1-based therapy versus S-1 monotherapy in advanced gastric cancer: a meta-analysis. <i>Tumor Biology</i> , 2014, 35, 3283-3293.	0.8	7
402	Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial. <i>Gastric Cancer</i> , 2014, 17, 711-717.	2.7	9
403	Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin). <i>Medical Oncology</i> , 2014, 31, 906.	1.2	8
404	Outcome Data of Patients with Peritoneal Carcinomatosis from Gastric Origin Treated by a Strategy of Bidirectional Chemotherapy Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in a Single Specialized Center in Japan. <i>Annals of Surgical Oncology</i> , 2014, 21, 1147-1152.	0.7	101
405	Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 829-837.	1.2	9
406	Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912. <i>Gastric Cancer</i> , 2014, 17, 522-528.	2.7	22
407	A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma. <i>Investigational New Drugs</i> , 2014, 32, 250-260.	1.2	5
408	Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. <i>Investigational New Drugs</i> , 2014, 32, 261-270.	1.2	14
409	Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 718-724.	2.7	20
410	Critical Evaluation of Disease Stabilization As a Measure of Activity of Systemic Therapy: Lessons From Trials With Arms in Which Patients Do Not Receive Active Treatment. <i>Journal of Clinical Oncology</i> , 2014, 32, 260-263.	0.8	19
411	Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen. <i>Medical Oncology</i> , 2014, 31, 153.	1.2	1
412	Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment. <i>International Journal of Clinical Oncology</i> , 2014, 19, 656-661.	1.0	9

#	ARTICLE	IF	CITATIONS
413	A Systematic Review of Randomized Controlled Trials Testing the Efficacy of Psychosocial Interventions for Gastrointestinal Cancers. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 181-189.	0.6	10
414	Hepatic resection of non-colorectal and non-neuroendocrine liver metastases – Survival benefit for patients with non-gastrointestinal primary cancers – A case-controlled study. <i>International Journal of Surgery</i> , 2014, 12, 163-168.	1.1	27
415	Optimal chemotherapy for advanced gastric cancer: is there a global consensus?. <i>Gastric Cancer</i> , 2014, 17, 213-225.	2.7	103
416	Treatment options in patients with metastatic gastric cancer: Current status and future perspectives. <i>World Journal of Gastroenterology</i> , 2014, 20, 3905.	1.4	77
417	Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer. <i>Oncology Letters</i> , 2014, 8, 351-354.	0.8	12
418	Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. <i>Oncology</i> , 2014, 87, 104-113.	0.9	28
419	2318 Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. <i>European Journal of Cancer</i> , 2015, 51, S438-S439.	1.3	0
420	Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1160-1164.	0.4	8
421	Corosolic acid enhances 5-fluorouracil-induced apoptosis against SNU-620 human gastric carcinoma cells by inhibition of mammalian target of rapamycin. <i>Molecular Medicine Reports</i> , 2015, 12, 4782-4788.	1.1	15
422	Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1281-1292.	2.3	11
423	Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. <i>SpringerPlus</i> , 2015, 4, 743.	1.2	10
424	Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer. <i>Ecological Management and Restoration</i> , 2015, 28, 782-787.	0.2	20
425	Management of cancer of the stomach. , 0, , 185-195.		0
427	Apatinib for the treatment of gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 117-122.	0.9	81
428	Retrospective Evaluation of the Efficacy of First-Line Treatment of Advanced Gastric Cancer With Docetaxel and Oxaliplatin. <i>Cancer Investigation</i> , 2015, 33, 16-21.	0.6	4
429	Paclitaxel-based regimens as first-line treatment in advanced gastric cancer. <i>Journal of Chemotherapy</i> , 2015, 27, 94-98.	0.7	17
430	Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer. <i>Pathology and Oncology Research</i> , 2015, 21, 867-873.	0.9	10
431	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 824-832.	2.7	91

#	ARTICLE	IF	CITATIONS
432	Surveillance After Gastric Resection. , 2015, , 255-270.		1
433	Update on Metastatic Gastric and Esophageal Cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 1760-1769.	0.8	181
434	Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. <i>Medical Oncology</i> , 2015, 32, 242.	1.2	32
435	Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 397-408.	1.1	32
436	Does surgery have a role in managing incurable gastric cancer?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 676-682.	12.5	96
437	Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer. <i>Annals of Oncology</i> , 2015, 26, 1838-1845.	0.6	15
438	Management of gastric cancer: East vs west. <i>Current Problems in Cancer</i> , 2015, 39, 315-341.	1.0	7
439	Gastric cancer: past progress and present challenges. <i>Gastric Cancer</i> , 2015, 18, 205-209.	2.7	7
440	Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution. <i>Gastric Cancer</i> , 2015, 18, 346-353.	2.7	23
441	A Case of Long-Term Complete Remission of Advanced Gastric Adenocarcinoma with Liver Metastasis. <i>Journal of Gastric Cancer</i> , 2016, 16, 115.	0.9	2
442	Chemotherapy in Elderly Patients with Gastric Cancer. <i>Journal of Cancer</i> , 2016, 7, 88-94.	1.2	36
443	Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. <i>BMC Cancer</i> , 2016, 16, 779.	1.1	3
444	Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review. <i>Pleura and Peritoneum</i> , 2016, 1, 67-77.	0.5	13
445	The efficiency and safety of trastuzumab for advanced gastric and gastroesophageal cancer: a meta-analysis of five randomized controlled trials. <i>Growth Factors</i> , 2016, 34, 187-195.	0.5	4
446	Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis. <i>Pathology and Oncology Research</i> , 2016, 22, 853-861.	0.9	8
447	Personalised Treatment in Gastric Cancer: Myth or Reality?. <i>Current Oncology Reports</i> , 2016, 18, 41.	1.8	16
448	Gastric cancer. <i>Lancet, The</i> , 2016, 388, 2654-2664.	6.3	1,560
449	Gastric/GE Junction Cancer. , 2016, , 906-933.e5.		3

#	ARTICLE	IF	CITATIONS
450	Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v38-v49.	0.6	1,212
451	Effect of oxaliplatin combined with polyenephosphatidylcholine on the proliferation of human gastric cancer SGC-7901 cells. <i>Oncology Letters</i> , 2016, 12, 4538-4546.	0.8	6
452	Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study. <i>European Radiology</i> , 2016, 26, 2771-2778.	2.3	31
453	Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?. <i>Annals of Surgical Oncology</i> , 2016, 23, 1971-1979.	0.7	132
454	The 100 most influential manuscripts in gastric cancer: A bibliometric analysis. <i>International Journal of Surgery</i> , 2016, 28, 83-90.	1.1	55
455	Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. <i>British Journal of Cancer</i> , 2016, 114, 505-509.	2.9	43
456	Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation. <i>Gastric Cancer</i> , 2016, 19, 951-960.	2.7	48
457	“What if I do nothing?” The natural history of operable cancer of the alimentary tract. <i>European Journal of Surgical Oncology</i> , 2017, 43, 788-795.	0.5	9
458	Second-line chemotherapy for patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 395-406.	2.7	31
459	Advanced gastric cancer: is there an optimal chemotherapy regimen?. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 123-132.	0.6	0
460	Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 583-589.	0.6	22
461	Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer. <i>Supportive Care in Cancer</i> , 2017, 25, 2771-2777.	1.0	3
463	The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy. <i>International Journal of Clinical Oncology</i> , 2017, 22, 887-896.	1.0	17
464	Third-line chemotherapy in advanced gastric cancer. <i>Medicine (United States)</i> , 2017, 96, e6884.	0.4	28
465	MicroRNA-21 contributes to the discrimination of chemoresistance in metastatic gastric cancer. <i>Cancer Biomarkers</i> , 2017, 18, 451-458.	0.8	14
466	Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?. <i>Annals of Oncology</i> , 2017, 28, 1207-1216.	0.6	31
467	Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 319-327.	1.0	11
468	Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. <i>Medical Oncology</i> , 2017, 34, 186.	1.2	7

#	ARTICLE	IF	CITATIONS
469	Chemotherapy for advanced gastric cancer. The Cochrane Library, 2017, 2017, CD004064.	1.5	662
470	Comparison of efficacy and tolerance between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer: Study protocol for a randomized controlled trial. Contemporary Clinical Trials Communications, 2017, 8, 55-61.	0.5	1
471	Treatment of lymph node metastases from gastric cancer with a combination of Irreversible Electroporation and Electrochemotherapy: a case report. Clinical Case Reports (discontinued), 2017, 5, 1389-1394.	0.2	10
472	Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer. Oncology Letters, 2017, 14, 2545-2551.	0.8	8
473	Milestones in gastric cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 33-37.	0.3	1
474	Jarcho's Syndrome: Bone Marrow Infiltrates from a Gastric Malignancy. Indian Journal of Surgery, 2017, 79, 268-269.	0.2	0
475	Fibroblast Activation Protein-Positive Fibroblasts Promote Gastric Cancer Progression and Resistance to Immune Checkpoint Blockade. Oncology Research, 2017, 25, 629-640.	0.6	69
476	Evaluation the Survival of Patients with Gastric Cancer Treated with Adjuvant or Palliative Chemotherapy. Journal of Gastrointestinal Cancer, 2017, 48, 31-37.	0.6	5
477	Postgastroectomy follow-up in the West: evidence base, guidelines, and daily practice. Gastric Cancer, 2017, 20, 135-140.	2.7	17
478	Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 351-363.	0.7	19
479	Prognostic factors in patients with loco-regionally advanced gastric cancer. World Journal of Surgical Oncology, 2017, 15, 172.	0.8	11
481	New chemotherapies in gastric adenocarcinoma. Memo - Magazine of European Medical Oncology, 2017, 10, 132-135.	0.3	0
482	Profiling chemotherapy-associated myelotoxicity among Chinese gastric cancer population receiving cytotoxic conventional regimens: epidemiological features, timing, predictors and clinical impacts. Journal of Cancer, 2017, 8, 2614-2625.	1.2	3
483	Gastric peritoneal carcinomatosis - a retrospective review. World Journal of Gastrointestinal Oncology, 2017, 9, 121.	0.8	27
484	A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer, 2018, 21, 782-791.	2.7	33
485	Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan. Gastric Cancer, 2018, 21, 1050-1057.	2.7	16
486	Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 1007-1015.	1.1	9
487	Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review. Gastric Cancer, 2018, 21, 183-195.	2.7	15

#	ARTICLE	IF	CITATIONS
489	Prognostic factors affecting outcomes in patients with malignant GI bleeding treated with a novel endoscopically delivered hemostatic powder. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 994-1002.	0.5	38
490	CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 559-569.	1.2	5
491	Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer. <i>Tumori</i> , 2018, 104, 22-29.	0.6	5
492	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476
493	Characteristics of Gastric Cancer in Lebanon: a Descriptive Study from a Single Institutional Experience. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 21-24.	0.6	8
494	Thalidomide combined with chemotherapy in treating elderly patients with advanced gastric cancer. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 499-505.	1.4	0
495	Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). <i>Gastric Cancer</i> , 2018, 21, 421-427.	2.7	28
496	Risk Factors for Chemotherapy-Related Toxicity and Adverse Events in Elderly Thai Cancer Patients: A Prospective Study. <i>Oncology</i> , 2018, 94, 149-160.	0.9	15
497	Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. <i>Gastric Cancer</i> , 2018, 21, 473-480.	2.7	21
498	Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 52-63.	0.6	26
499	Should S-1 be better than capecitabine for patients with advanced gastric cancer in Asia? A systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 12, 269-277.	1.0	2
500	The surgical and oncological outcomes of conversion surgery for patients with initially unresectable gastric cancer. <i>Annals of Cancer Research and Therapy</i> , 2018, 26, 89-94.	0.1	0
501	New drug developments in metastatic gastric cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880807.	1.4	19
502	A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study. <i>PLoS ONE</i> , 2018, 13, e0205853.	1.1	10
503	The safety of apatinib for the treatment of gastric cancer. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1145-1150.	1.0	49
504	Hyperthermic Intraperitoneal Chemotherapy - Fading Perspective in the Light of Modern Systemic Chemotherapy?. <i>Visceral Medicine</i> , 2018, 34, 412-416.	0.5	8
505	Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study. <i>PLoS ONE</i> , 2018, 13, e0198544.	1.1	21
506	Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 375-381.	1.0	11

#	ARTICLE	IF	CITATIONS
507	Ramucirumab for the treatment of gastric adenocarcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 449-455.	0.5	0
508	Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1805-1810.	0.5	38
509	Immunotherapy in Advanced Gastric Cancer: An Overview of the Emerging Strategies. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-8.	0.8	15
510	Metastatic gastric cancer: Does the site of metastasis make a difference?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 10-17.	0.7	14
511	Prognostic Indicators in Stage IV Surgically Treated Gastric Cancer Patients: A Retrospective Multi-Institutional Study. <i>Digestive Surgery</i> , 2019, 36, 331-339.	0.6	2
512	Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 12-29.	3.0	25
513	Surgical management of metastatic gastric cancer: moving beyond the guidelines. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 58-58.	1.5	25
514	The use of intraperitoneal chemotherapy for gastric malignancies. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 879-888.	1.1	20
515	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). <i>Annals of Surgical Oncology</i> , 2019, 26, 2615-2621.	0.7	56
516	Retrospective analysis of patients with advanced or metastatic gastric cancer in Colombia. <i>Journal of Medical Economics</i> , 2019, 22, 891-900.	1.0	2
517	Prediction of Treatment Outcome of Chemotherapy Using Perfusion Computed Tomography in Patients with Unresectable Advanced Gastric Cancer. <i>Korean Journal of Radiology</i> , 2019, 20, 589.	1.5	4
518	Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials. <i>International Journal of Clinical Oncology</i> , 2019, 24, 614-623.	1.0	18
519	Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. <i>Molecular Cancer</i> , 2019, 18, 68.	7.9	169
520	Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. <i>Journal of Gastric Cancer</i> , 2019, 19, 1.	0.9	328
521	Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1308.	1.3	82
523	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 19-33.	0.6	165
524	Oncological outcomes after hepatic resection and/or surgical microwave ablation for liver metastasis from gastric cancer. <i>Asian Journal of Surgery</i> , 2019, 42, 100-105.	0.2	24
525	Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5500.	1.8	25

#	ARTICLE	IF	CITATIONS
526	The combination of Biochanin A and SB590885 potentiates the inhibition of tumour progression in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2020, 20, 371.	1.8	19
527	Gastric cancer. <i>Lancet, The</i> , 2020, 396, 635-648.	6.3	2,084
528	Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020. <i>Annals of Translational Medicine</i> , 2020, 8, 1109-1109.	0.7	6
529	Targeted therapies for gastroesophageal cancers. <i>Annals of Translational Medicine</i> , 2020, 8, 1104-1104.	0.7	9
530	The Prognostic Value of Neutrophil-to-lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Metastatic Gastric Cancer Treated with Systemic Chemotherapy. <i>Journal of Cancer</i> , 2020, 11, 4205-4212.	1.2	25
531	The Effectiveness of Gastrectomy With Chemoradiotherapy Among Stage IV Gastric Adenocarcinoma: A Population-Based Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 630.	1.3	5
532	Emerging precision therapies for gastric cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 299-311.	0.4	1
533	Impact of multidisciplinary tumor board discussion on palliation of patients with esophageal or gastro-esophageal junction cancer: a population-based study. <i>Acta OncolÃ³gica</i> , 2020, 59, 410-416.	0.8	8
534	Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma. <i>Anticancer Research</i> , 2020, 40, 965-975.	0.5	12
535	Patient-reported symptoms in metastatic gastric cancer patients in the last 6 months of life. <i>Supportive Care in Cancer</i> , 2021, 29, 515-524.	1.0	12
536	REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer. <i>Future Oncology</i> , 2021, 17, 869-875.	1.1	6
537	Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 535-546.	1.1	9
538	BRAZILIAN GASTRIC CANCER ASSOCIATION GUIDELINES (PART 2): UPDATE ON TREATMENT. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2021, 34, e1563.	0.5	12
539	First-Line Palliative Chemotherapy for Esophageal and Gastric Cancer: Practice Patterns and Outcomes in the General Population. <i>JCO Oncology Practice</i> , 2021, 17, e1537-e1550.	1.4	6
540	Palliative Gastrectomy versus Gastrojejunostomy for advanced Gastric cancer with outlet obstruction: a propensity score matching analysis. <i>BMC Cancer</i> , 2021, 21, 188.	1.1	15
541	Current status of doublet combinations of platinum and fluoropyrimidines using oxaliplatin for advanced gastric cancer. <i>Global Health & Medicine</i> , 2021, 3, 31-36.	0.6	6
542	Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 1079.	1.0	11
543	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 473-487.	12.5	139

#	ARTICLE	IF	CITATIONS
544	Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 232-238.	0.6	4
545	A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas. <i>Medicine (United States)</i> , 2021, 100, e25493.	0.4	2
546	Chemotherapy After Diagnosis of Malignant Bowel Obstruction is Associated with Superior Survival for Medicare Patients with Advanced Malignancy. <i>Annals of Surgical Oncology</i> , 2021, 28, 7555-7563.	0.7	7
547	Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. <i>Journal of Translational Medicine</i> , 2021, 19, 184.	1.8	21
548	AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study. <i>Acta Oncologica</i> , 2021, 60, 785-793.	0.8	5
549	The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer. <i>Cureus</i> , 2021, 13, e14882.	0.2	2
550	Successful conversion therapy through gastric transcatheter chemoembolization in advanced gastric cancer: A case report. <i>Asian Journal of Surgery</i> , 2021, 44, 867-868.	0.2	0
551	Advances in Systemic Therapy for Gastric Cancer. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2021, 31, 607-623.	0.6	11
552	Recent advances in gastrointestinal cancers. <i>World Journal of Gastroenterology</i> , 2021, 27, 4493-4503.	1.4	11
553	Psycho-Oncology: A Bibliometric Review of the 100 Most-Cited Articles. <i>Healthcare (Switzerland)</i> , 2021, 9, 1008.	1.0	4
554	Aberrant lipid metabolism reprogramming and immune microenvironment for gastric cancer: a literature review. <i>Translational Cancer Research</i> , 2021, 10, 3829-3842.	0.4	8
555	Nutritional Support Indications in Gastroesophageal Cancer Patients: From Perioperative to Palliative Systemic Therapy. A Comprehensive Review of the Last Decade. <i>Nutrients</i> , 2021, 13, 2766.	1.7	22
556	Predicting Response to Systemic Chemotherapy for Advanced Gastric Cancer Using Pre-Treatment Dual-Energy CT Radiomics: A Pilot Study. <i>Frontiers in Oncology</i> , 2021, 11, 740732.	1.3	7
557	Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2022, 17, 26-41.	0.8	15
558	Antitumor activity studies of iridium (III) polypyridine complexes-loaded liposomes against gastric tumor cell in vitro. <i>Journal of Inorganic Biochemistry</i> , 2021, 225, 111603.	1.5	7
559	Advances in clinical immunotherapy for gastric cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188615.	3.3	153
560	Current state of chemotherapy and immunotherapy regimens in gastric cancer. , 2021, , 289-316.		0
561	âœSweet toothâœ-oriented SN38 prodrug delivery nanoplatfrom for targeted gastric cancer therapy. <i>Journal of Materials Chemistry B</i> , 2021, 9, 2816-2830.	2.9	10

#	ARTICLE	IF	CITATIONS
562	Magenkarzinom. , 2006, , 445-481.		2
564	Cancer of the Stomach. , 2008, , 1431-1464.		3
565	Gastric/GE Junction Cancer. , 2012, , 903-933.		4
566	Chemotherapy in gastric cancer: a review and updated meta-analysis. The European Journal of Surgery, 2002, 168, 597-608.	1.0	199
567	Gastric Adenocarcinoma. Annals of Surgery, 2005, 241, 27-39.	2.1	621
568	Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001. Anti-Cancer Drugs, 2008, 19, 535-539.	0.7	12
569	Guidelines for the management of oesophageal and gastric cancer. Gut, 2002, 50 Suppl 5, v1-23.	6.1	72
570	Prognostic and Predictive Role of HER2 Expression in Metastatic Gastric Cancer in Turkish Patients. Cancer Research Journal, 2013, 1, 20.	0.0	1
571	CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer. BMC Cancer, 2020, 20, 468.	1.1	40
572	Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing. Medical Science Monitor. 2011, 17, CR248-CR258.	0.5	7
573	Clinical Complete Response from Chemotherapy in an Elderly Patient with Metastatic Gastric Cancer: A Case Report. Journal of Nippon Medical School, 2016, 83, 199-202.	0.3	3
574	Outcomes of advanced gastric cancer in young adult patients treated with first-line combination chemotherapy. International Journal of Cancer Therapy and Oncology, 2015, 3, 344.	0.2	1
575	Tratamento paliativo do adenocarcinoma gástrico. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2011, 24, 74-80.	0.5	1
576	Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients. Oncotarget, 2017, 8, 30495-30501.	0.8	5
577	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget, 2010, 1, 515-529.	0.8	12
578	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. Oncotarget, 2016, 7, 24088-24096.	0.8	15
579	Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status. Translational Cancer Research, 2019, 8, 1690-1698.	0.4	4
580	Critical appraisal of trastuzumab in treatment of advanced stomach cancer. Cancer Management and Research, 2011, 3, 57.	0.9	19

#	ARTICLE	IF	CITATIONS
581	Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2337-2341.	0.5	6
583	New perspectives in the treatment of advanced or metastatic gastric cancer. World Journal of Gastroenterology, 2009, 15, 2689.	1.4	37
584	Chemotherapy for gastric cancer. World Journal of Gastroenterology, 2006, 12, 204.	1.4	88
585	Irinotecan-involved regimens for advanced gastric cancer: A pooled-analysis of clinical trials. World Journal of Gastroenterology, 2010, 16, 5889.	1.4	10
586	Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer. World Journal of Gastroenterology, 2011, 17, 1082.	1.4	17
587	Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg. World Journal of Gastroenterology, 2015, 21, 4911.	1.4	9
588	Second-line treatment of metastatic gastric cancer: Current options and future directions. World Journal of Gastroenterology, 2015, 21, 11621.	1.4	32
589	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World Journal of Gastroenterology, 2016, 22, 1114.	1.4	75
590	Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction. Korean Journal of Internal Medicine, 2006, 21, 252.	0.7	6
591	FOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer. Korean Journal of Medicine, 2012, 82, 37.	0.1	2
592	Recent Advances in Chemotherapy of Gastric Cancer. Korean Journal of Medicine, 2012, 82, 417.	0.1	3
593	Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2012, 24, 291-8.	0.7	11
594	Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. Journal of Gastrointestinal Oncology, 2014, 5, 57-66.	0.6	5
595	Long Term Complete Remission in Advanced Gastric Adenocarcinoma With Docetaxel, Oxaliplatin and Capecitabine Combination Regimen. World Journal of Oncology, 2012, 3, 124-126.	0.6	4
596	5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: A retrospective analysis of 68 patients. Indian Journal of Cancer, 2005, 42, 85.	0.2	8
597	Pathogenesis and treatment of gastric carcinoma: "An up-date with brief review". Journal of Cancer Research and Therapeutics, 2006, 2, 196.	0.3	32
598	Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India. Indian Journal of Cancer, 2017, 54, 47.	0.2	6
599	Retrospective study of oxaliplatin, leucovorin and 5 fluoruracil regimen in patients with advanced gastric cancer with poor performance status: A study at a tertiary center of South India. South Asian Journal of Cancer, 2018, 07, 223-225.	0.2	2

#	ARTICLE	IF	CITATIONS
600	Salvage Treatment for Advanced Gastric Cancer Using FEP (5-FU, Etoposide, Cisplatin) Combination Chemotherapy. <i>Cancer Research and Treatment</i> , 2002, 34, 382-387.	1.3	4
601	Randomized Phase III Trial of Cisplatin, Epirubicin, Leucovorin, 5-Fluorouracil (PELF) Combination versus 5-fluorouracil Alone as Adjuvant Chemotherapy in Curative Resected Stage III Gastric Cancer. <i>Cancer Research and Treatment</i> , 2004, 36, 140.	1.3	10
602	The Efficacy of Docetaxel and Cisplatin Combination Chemotherapy for the Treatment of Advanced Gastric Cancer after Failing to 5-Fluorouracil Based Chemotherapy. <i>Cancer Research and Treatment</i> , 2004, 36, 367.	1.3	3
603	Chemotherapy for Advanced Gastric Cancer: Slow but Further Progress. <i>Cancer Research and Treatment</i> , 2005, 37, 79.	1.3	15
604	Efficacy and Safety Study of Docetaxel as Salvage Chemotherapy in Metastatic Gastric Cancer Failing Fluoropyrimidine and Platinum Combination Chemotherapy. <i>Cancer Research and Treatment</i> , 2005, 37, 201.	1.3	5
605	A Multi-Center, Phase II Clinical Trial of Padexolâ,ç (Paclitaxel) and Cisplatin for Patients Suffering with Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2005, 37, 349.	1.3	8
606	A Pilot Study of Cisplatin, Irinotecan, Leucovorin and 5-fluorouracil (PILF) Combination Chemotherapy for Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2006, 38, 121.	1.3	1
607	Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric Cancer. <i>Cancer Research and Treatment</i> , 2007, 39, 99.	1.3	23
608	A Phase II Trial of Paclitaxel, 5-fluorouracil (5-FU) and Cisplatin in Patients with Metastatic or Recurrent Gastric Cancer. <i>Cancer Research and Treatment</i> , 2008, 40, 106.	1.3	7
609	Outcomes of Modified FOLFOX-6 as First Line Treatment in Patients with Advanced Gastric Cancer in a Single Institution; Retrospective Analysis. <i>Cancer Research and Treatment</i> , 2010, 42, 18.	1.3	16
610	Oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX-4) Combination Chemotherapy as a Salvage Treatment in Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2010, 42, 24.	1.3	26
611	Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2011, 43, 148-153.	1.3	12
612	Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer. <i>Cancer Research and Treatment</i> , 2011, 43, 154-159.	1.3	10
613	Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2011, 43, 236-243.	1.3	15
614	Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies. <i>Cancer Research and Treatment</i> , 2012, 44, 235-241.	1.3	23
615	A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine. <i>Cancer Research and Treatment</i> , 2017, 49, 706-716.	1.3	17
616	Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 223-239.	1.3	13
617	Role of Chemotherapy in Advanced Gastric Cancer: Review from a Latin American Perspective. <i>Journal of Cancer Therapy</i> , 2016, 07, 1-12.	0.1	2

#	ARTICLE	IF	CITATIONS
618	Gastric cancer with peritoneal metastases: Efficiency of standard treatment methods. World Journal of Gastrointestinal Oncology, 2020, 12, 569-581.	0.8	21
619	Recent advances in chemotherapy for advanced gastric cancer. World Journal of Gastrointestinal Oncology, 2010, 2, 287.	0.8	5
620	Three-Weekly S-1 Monotherapy as First-Line Treatment in Elderly Patients with Recurrent or Metastatic Gastric Cancer. Gut and Liver, 2010, 4, 503-507.	1.4	7
621	Targeting metastatic upper gastrointestinal adenocarcinomas. World Journal of Clinical Oncology, 2011, 2, 135.	0.9	4
622	HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. BMB Reports, 2018, 51, 660-665.	1.1	14
623	Prognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Study. Asian Pacific Journal of Cancer Prevention, 2012, 13, 3869-3872.	0.5	9
624	Neutrophil Count and the Inflammation-based Glasgow Prognostic Score Predict Survival in Patients with Advanced Gastric Cancer Receiving First-line Chemotherapy. Asian Pacific Journal of Cancer Prevention, 2014, 15, 945-950.	0.5	79
625	Modified Docetaxel and Cisplatin in Combination with Capecitabine (DCX) as a First-Line Treatment in HER2-Negative Advanced Gastric Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8661-8666.	0.5	8
626	Prognostic Significance of p53 in Gastric Cancer: a Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 2015, 16, 327-332.	0.5	43
627	Clinical Characteristics Associated with Long-term Survival in Metastatic Gastric Cancer after Systemic Chemotherapy. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5433-5438.	0.5	6
628	Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance Status. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2355-2359.	0.5	5
629	Magenkarzinom. , 2002, , 585-594.		0
630	Ileocaecal Interpositional Graft as a Gastric Substitute. , 2003, , 67-109.		0
631	Gastrointestinal Cancers. Medical Radiology, 2003, , 49-80.	0.0	0
632	Magenkarzinom. , 2003, , 163-200.		0
633	Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer. Cancer Research and Treatment, 2003, 35, 123-129.	1.3	1
634	Tratamiento del carcinoma diseminado de estómago: ¿pauta estándar?. Oncología, 2004, 27, .	0.0	1
635	Chemotherapy for Cancer Pain Management. , 2006, , 459-464.		0

#	ARTICLE	IF	CITATIONS
636	Magenkarzinom. , 2006, , 3737-3768.		1
637	GASTROJEJUNOSTOMY FOR OBSTRUCTING DISTAL GASTRIC CANCER. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2007, 68, 1064-1069.	0.0	0
639	Trends in incidence, management, and survival of gastric and cardia carcinomas in the area of Finistere (France) between 1984 and 2003. European Journal of Gastroenterology and Hepatology, 2010, 22, 1.	0.8	8
640	Prise en charge de lâ€™adâ€™necarcinome mâ€™tastatique de lâ€™estomac. , 2011, , 175-183.		0
642	Design of precise third-line therapy for gastric cancer: target or chemotherapy?. Korean Journal of Internal Medicine, 2013, 28, 297.	0.7	0
643	Dose-Dense Regimen of Cisplatin and Infusional Fluorouracil in Advanced Gastric Cancerâ€™A Single Institution Experience. Journal of Cancer Therapy, 2013, 04, 529-535.	0.1	0
644	Chemotherapy for Advanced Gastric Cancer in Elderly Patients. Korean Journal of Medicine, 2014, 87, 521.	0.1	0
645	Cancer of the Stomach and Gastroesophageal Junction. , 2014, , 1240-1270.e7.		1
646	The results of primary chemotherapy of TS-1/cisplatin regimen in unresectable or metastatic gastric cancer patients. Korean Journal of Clinical Oncology, 2014, 10, 41-45.	0.1	0
648	Clinical Practice Guidelines of Korean Medicine for Gastric Cancer. Journal of Korean Traditional Oncology, 2014, 19, 1-24.	0.0	1
649	Survival Effect of Supportive Care Services for Turkish Patients with Metastatic Gastric Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1213-1217.	0.5	1
650	Systemic Treatment of Esophageal Cancer. , 2016, , 325-344.		0
651	Dominated by Professional Nurse Nutritional Intervention in Patients with Terminal Gastrointestinal Tumor Chemotherapy: An Integrative Research. Nursing Science, 2016, 05, 75-80.	0.0	0
652	Gastric Adenocarcinoma. , 2016, , 137-148.		0
653	Gastric Cancer in the Elderly. , 2017, , 1-26.		0
655	Safe use of capecitabine-cisplatin in metastatic gastric carcinoma with severe liver dysfunction: a case report from Algeria. Electronic Physician, 2017, 9, 4942-4945.	0.2	0
656	Reduced Doses of Docetaxel and Cisplatin Plus 5 Fluorouracil Combination Chemotherapy in Metastatic Esophagogastric Adenocarcinoma: The Impact on Outcomes. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2017, 27, 171-177.	0.1	0
657	Comparison of health-related quality of life with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil chemotherapy regimens as first-line systemic therapy in locally advanced inoperable or metastatic gastric or gastro-esophageal junction adenocarcinoma: A prospective study from South India. South Asian Journal of Cancer, 2018, 07, 11-15.	0.2	1

#	ARTICLE	IF	CITATIONS
658	A clinical case of long-term remission of disseminated gastric cancer. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2018, 7, 48.	0.0	1
659	Outcomes with Palliative Weekly Paclitaxel in Advanced, Recurrent, and Metastatic Esophageal Cancer -Real World Experience. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2018, 39, 46-51.	0.1	0
660	The Role of Chemotherapy. , 2018, , 65-75.		0
661	CHEMOTHERAPY IN ELDERLY PATIENTS WITH STOMACH CANCER. <i>Malignant Tumours</i> , 2018, 8, 64-75.	0.1	2
662	Treatment of Patients with Advanced Gastroesophageal Adenocarcinoma: Does Age Matter?. <i>Drugs and Aging</i> , 2019, 36, 403-409.	1.3	0
663	Treatment in resectable non-metastatic adenocarcinoma of stomach: Changing paradigms. <i>Indian Journal of Cancer</i> , 2019, 56, 74.	0.2	2
664	Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study. <i>South Asian Journal of Cancer</i> , 2019, 08, 085-087.	0.2	1
665	Gastric Adenocarcinoma. , 2020, , 199-223.		0
666	S-1 Plus Leucovorin and Oxaliplatin in Combination with Lentinan as First-line Therapy in Patients with Metastatic Gastric Cancer. <i>Journal of Cancer Research Updates</i> , 0, 9, 69-74.	0.3	0
667	Gastric Cancer in the Elderly. , 2020, , 931-956.		0
668	Survival outcomes with docetaxel, oxaliplatin, and fluorouracil regimen for the treatment of metastatic gastric adenocarcinoma: A single-center experience. <i>Oncology Journal of India</i> , 2020, 4, 110.	0.1	0
670	Palliative Therapy. , 2005, , 299-312.		0
672	Magenkarzinom. , 0, , 679-691.		0
673	Signature based on molecular subtypes of deoxyribonucleic acid methylation predicts overall survival in gastric cancer. <i>World Journal of Gastroenterology</i> , 2020, 26, 6414-6430.	1.4	3
674	Latest developments and emerging treatment options in the management of stomach cancer. <i>Cancer Management and Research</i> , 2011, 3, 257.	0.9	15
675	Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, 187-97.	0.8	7
676	Advanced gastric cancer: an update and future directions. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, S47-53.	0.8	6
677	Refining docetaxel-containing therapy for gastric cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2011, 4, 96-105.	0.8	3

#	ARTICLE	IF	CITATIONS
678	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. <i>Oncotarget</i> , 2010, 1, 515-29.	0.8	9
679	Advanced gastric cancer in Jordan from 2004 to 2008: a study of epidemiology and outcomes. <i>Gastrointestinal Cancer Research: GCR</i> , 2011, 4, 122-7.	0.8	13
680	Gastric cancer: toward a cisplatin-free disease?. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 318-22.	0.6	2
681	Synergistic Effect of Forbesione From <i>Garcinia hanburyi</i> in Combination with 5-Fluorouracil on Cholangiocarcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 3343-3351.	0.5	6
682	Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer. <i>Journal of Nanobiotechnology</i> , 2021, 19, 381.	4.2	22
683	Economic cost-utility analysis of stage-directed gastric cancer treatment. <i>BJS Open</i> , 2021, 5, .	0.7	0
684	A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology. <i>Molecular Cancer</i> , 2022, 21, 9.	7.9	2
685	Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018. <i>Oncologist</i> , 2022, 27, e506-e517.	1.9	6
686	Stomach: The Standard of Care ± HER2. , 2021, , 75-88.		0
687	Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 167-192.	2.3	562
689	A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines. <i>Journal of Gastric Cancer</i> , 2022, 22, 3.	0.9	34
690	PD-L1 immunohistochemistry comparison of 22C3 and 28-8 assays for gastric cancer. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2696-2705.	0.6	14
691	Development and external validation of a prognostic nomogram for patients with gastric cancer after radical gastrectomy. <i>Annals of Translational Medicine</i> , 2021, 9, 1742-1742.	0.7	3
696	PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
697	Polyphenol Mechanisms against Gastric Cancer and Their Interactions with Gut Microbiota: A Review. <i>Current Oncology</i> , 2022, 29, 5247-5261.	0.9	9
698	End-of-life care of patients with esophageal or gastric cancer: decision making and the goal of care. <i>Acta Oncologica</i> , 2022, 61, 1173-1178.	0.8	1
699	The seen and the unseen: Molecular classification and image based-analysis of gastrointestinal cancers. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5065-5075.	1.9	0
700	ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8+ T Cell Cytotoxicity. <i>Journal of Immunology Research</i> , 2022, 2022, 1-16.	0.9	3

#	ARTICLE	IF	CITATIONS
703	Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
704	Signaling pathways and therapeutic interventions in gastric cancer. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	54
706	TrÃ±plet or Doublet Chemotherapy Regimens in Metastatic Gastric Cancer. <i>Clinical Cancer Investigation Journal</i> , 2022, 11, 41-45.	0.2	3
708	Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery for gastric carcinoma at high risk of peritoneal carcinomatosis: short and long-term outcomes (GOETH STUDY)â€”a collaborative randomized controlled trial by ACOI, FONDAZIONE AIOM, SIC, SICE, and SICO. <i>Trials</i> , 2022, 23, .	0.7	1
709	Safety and Efficacy of Simultaneous Resection of Gastric Carcinoma and Synchronous Liver Metastasisâ€”A Western Center Experience. <i>Medicina (Lithuania)</i> , 2022, 58, 1802.	0.8	1
710	Repurposed Drugs in Gastric Cancer. <i>Molecules</i> , 2023, 28, 319.	1.7	1
711	Neutrophilâ€™toâ€™lymphocyte ratio before each chemotherapy line predicts clinical outcomes in patients with unresectable gastric cancer. <i>Oncology Letters</i> , 2023, 25, .	0.8	2
712	Updated Immunotherapy for Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 2636.	1.0	6
713	Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases. , 2023, 11, e006280.		5
719	Targeted therapy and drug resistance in gastric and pancreatic cancer. , 2023, , 183-206.		0
721	Magenkarzinom. <i>Springer Reference Medizin</i> , 2023, , 1-49.	0.0	0
730	Clinical Management of Gastric Cancer Treatment Regimens. <i>Current Topics in Microbiology and Immunology</i> , 2023, , 279-304.	0.7	0